کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
PFAPA and 12 Common MEFV Gene Mutations

Our Clinical Experience

Farhad Salehzadeh, MD; Maryam Vahedi, MD; Saeid Hosseini-Asl, MD; Sepideh Jahangiri, MD; Shahram Habibzadeh, MD; Mahsa Hosseini-Khotbesara, MD

Department of Pediatric, Ardabil University of Medical Sciences, Ardabil, Iran

Received: Jan 09, 2013; Accepted: Sep 29, 2013; First Online Available: Nov 27, 2013

Abstract

Objective: Marshall Syndrome or PFAPA is an inflammatory periodic disease characterized by periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis. Although PFAPA is an auto inflammatory disease, it doesn't have genetic basis such as other periodic fevers. This study evaluates the 12 common MEFV gene mutations in patients with PFAPA syndrome.

Methods: 21 patients with PFAPA syndrome who had diagnostic criteria were enrolled in this study and 12 common MEFV gene mutations i.e. P369S, F479L, M680I (G/C), M680I (G/A), I692del, M694V, M694I, K695R, V726A, A744S, R761H, E148Q evaluated. All the patients were screened for MEFV gene mutations by a reverse hybridization assay (FMF Strip Assay, Vienna lab, Vienna, Austria) according to the instructions provided by the manufacturer.

Findings: The age of patients was between 6 months to 14 years, and 15 were males. Seven patients had heterozygote and one had compound heterozygote (K695R, V725A) mutation. There were 4 alleles M694V, 3 alleles V726A, 1 allele E148Q and 1 allele K694R. No significant difference existed between mutated patients with non-mutated in symptoms like aphthous and stomatitis, duration of attacks, episodes of fever and response to treatment. Gaslini score test was not helpful to predict the probability of gene mutations.

Conclusion: About 30 percent of patients had MEFV gene mutations but these mutations did not play a main role in presentation of PFAPA symptoms.

Key Words: PFAPA; Gaslini Score; MEFV Gene; MEFV Gene Mutations

Introduction

Marshall Syndrome was first defined by Marshal in 1987[1]. The acronym FAPA (fever, aphthous stomatitis, pharyngitis, cervical adenitis) was was later renamed to PFAPA (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis)[2]. This clinical syndrome occurs among children less than 5 years old. It is a sporadic disease with periodic attacks of inflammation[3]. Periodic fevers usually last 3 to 6 days and occur with regular intervals about every 3 to 6 weeks. The diagnosis is established on the basis of clinical criteria that require the presence of a recurrent fever of early onset (<5 years) and ≥1 of the 3 associated symptoms (aphthosis, cervical adenitis, and pharyngitis) in the absence of upper respiratory tract infections and cyclic neutropenia[2].
Between episodes, the children usually are well. The exact cause of PFAPA is unknown and autoimmune or infectious processes in its pathogenesis are not proven. Moreover, no geographical or ethnic tendencies have been shown. WBC and ESR are increased during acute episodes[4]. Because a single dose of corticosteroid can resolve attacks, inflammatory cytokines production in response to infectious factors is considered as a leading cause of the syndrome. IFN-γ, TNF and IL-6 increase during episodes[5,6]. It is more common in males and the prognosis is very good[7,8].

PFAPA has been reported in adult patients too[9,10]. Although PFAPA is a periodic fever, no specific gene mutation is known for it. Nevertheless it is possible that genes involved in other inflammatory diseases play a role in its pathogenesis[2].

In Cazeneuve’s study among 12 allele analysis only one mutation of M694V was found[11]. Berkun study showed that in PFAPA patients with MEFV gene mutation the disease was less severe and aphthous stomatitis, duration of disease, number of attacks, and need to steroid were less common. Therefore they found MEFV gene effect as a modifier on PFAPA[12].

In a study on 393 children with PFAPA, the clinical features were compared in genetically negative and positive results. 82 had positive genetic results, 75 uncertain and 236 negative results. In patients with positive genetic results diarrhea, vomiting, arthralgia and rash was more frequent. In the genetically negative group exudative pharyngitis was encountered more frequently[13].

Gattorno et al evaluated the relationship between PFAPA and other periodic fevers such as FMF, MVK, and TRAPS. They found a close relationship between PFAPA and other periodic fever syndromes[14].

FMF is an autosomal recessive disease characterized by acute attacks of fever and polyserositis. This disease mainly occurs in Mediterranean population and is caused by MEFV gene mutations[2]. This study was designed to analyse 12 most common MEFV gene mutations in PFAPA patients and also evaluating Gaslini score test based on detected mutations.

### Subjects and Methods

Twenty one patients who had diagnostic criteria were enrolled in this study. Twelve common MEFV gene mutations were evaluated: P369S, F479L, M680I(G/C), M680I(G/A), 1692del, M694V, M694I, K695R, V726A, A744S, R761H, E148Q. All the patients were screened for 12 common MEFV mutations by a reverse hybridization assay (FMF StripAssay, Vienna lab, Vienna, Austria) according to the instructions provided by the manufacturer. Statistical analysis was performed using SPSS 16.0. Comparison between the different genotypes was assessed using chi-square test. A P-value <0.05 was accepted as statistically significant.

### Findings

The age of patients was between 6 months and 14 years, and 15 were males. The mean age at onset of symptoms was 1.52±2.72 years (range 6 months - 5 years). The mean duration of fever was 3.57±1.64 days, and that of the disease 4.23±1.56 days. The interval of the attacks was 32.52±20.53 days. All of the patients had fever and 12 (57.14%) patients had abdominal pain, 19 (90.47%) children were breast fed infants.

In family history one patient’s brother, one patient’s father and one patient’s mother had FMF. Eight (38.09%) patients had MEFV gene mutations, seven of them were heterozygotes and one was combined heterozygous (K695R, V725A). (Table 1).

Although abdominal pain, aphthous stomatitis and duration of attacks were more common in non-mutated patients, these findings in association with episodes of fever and response to treatment did not show meaningful difference between the two groups (P≤0.05).

| Table 1: Prevalence of MEFV gene mutations |
|------------------------------------------|
| **MEFV Gene** | **Prevalence** | **Percent** |
|---------------|---------------|-------------|
| M694V         | 4             | 45          |
| V726A         | 3             | 33          |
| K694R         | 1             | 11          |
| E148Q         | 1             | 11          |
Table 2: Clinical findings in different studies

| Signs and symptoms          | Our study % | Gattorno(14) % | Stojanov(15) % | Padeh(8) % | Dagan(16) % |
|-----------------------------|-------------|----------------|----------------|------------|-------------|
| Fever                       | 100         | --             | 78             | 100        | --          |
| Weakness and lethargy       | 71.42       | --             | --             | 100        | --          |
| Skin rash                   | 14.28       | 24             | 18             | --         | --          |
| Headache                    | 28.6        | 46             | 6.5            | 17.8       | --          |
| Oral aphthosis              | 47.61       | 63             | 13             | 67.8       | 33.3        |
| Abdominal pain              | 57.14       | 68             | 42             | 17.8       | 35.1        |
| Myalgia                     | 61.9        | 3.5            | --             | --         | --          |
| Diarrhea                    | --          | 36             | --             | --         | --          |
| Vomiting                    | --          | 41             | --             | --         | --          |
| Arthralgia                  | 13          | 49             | --             | 10.7       | --          |

Discussion

Padeh[8], Stojanov[15] and Dagan[16] studies in comparison with our results are shown in Table 2. Table 3 shows our results and those of Gattorno.

Bonyadi revealed that the carrier rate of five common MEFV genes in the Azeri Turkish population was 25.5%, with E148Q being the most common (11.5%) mutation followed by V726A (1.75%). This study indicates that the FMF carrier rate and E148Q mutation frequency are high in the Iranian Azeri Turkish population[17] and one of our studies showed the frequency of E148Q mutation in FMF patients to be 9.95% (in press). It does not seem that these MEFV mutations in PFAPA patients are related to normal population varieties.

The authors have known two siblings suffering from FMF with M694V – V726A gene mutation, and PFAPA syndrome, offspring of whom had monozygotic mutation M694V and the other monozygotic mutation V726A.

In other authors’ experience there were 2 patients who had FMF and PFAPA simultaneously, it was observed that the first patient had R761H-M694I combined mutations and the second one M680I monozygotic mutation.

It seems that there is a genetic similarity, on the basis of pathogenesis, between FMF and PFAPA. This genetic similarity has led to suggest a scoring

Table 3: MEFV genes mutations in two studies

| Heterozygote                | Our study No of Mutation= 8 | Gattorno(14) No of Mutation= 40 |
|-----------------------------|-----------------------------|---------------------------------|
| Number                      | 1                           | 7                               |
| Compound Heterozygote       | Type of Mutation            | K695R/ V726A                    |
| Number                      | 7                           | 33                              |
| Type of Mutation            | M694V/V726A                 | E148Q (11)                      |
|                             | M680I/V726A                 | K695R (5)                       |
|                             | M694V/E148Q                 | M694V (4)                       |
|                             | L110P/L110P                 | A744S (3)                       |
|                             | V726A/E148Q                 | V726A (2)                       |
|                             | V726A/S108R                 | P369S/R408Q                     |
|                             | P369S/R408Q                 |                                 |
| Heterozygote                | Type of Mutation            | M694V (4)                       |
|                             | V726A (2)                   |                                 |
|                             | E148Q (1)                   |                                 |
system in genetic analysis of periodic fever syndromes in PFAPA patients[13]. This scoring is based on clinical criteria and is called Gaslini diagnostic score. If a PFAPA patient has scored above 1.32, he/she will be in a high risk of having others periodic fever syndromes.

In Gattorno study it was observed that Gaslini diagnostic score is a useful diagnostic tool in evaluating differential diagnosis of PFAPA syndrome.

Because 38 percent of PFAPA patients in this study had MEFV gene mutations, it seems that genetic basis of FMF has a role in pathogenesis of PFAPA; however there is no significant difference between mutation positive and negative patients in duration of disease, episodes of disease and response to treatment. Table 4 shows patients' Gaslini diagnostic scoring test.

**Conclusion**

This scoring was not helpful to predict the probability of MEFV gene mutation (12 common mutations) in our study and in these patients it has also been shown that MEFV gene mutation doesn't have any specific effect in patient's clinical manifestations. We should find another way to predict the presence of MEFV gene mutations in this syndrome.

**Authors' Contribution**

Concept / Design: F. Salehzadeh  
Acquisition of Data: M. Vahedi, M. Hosseini-Khotbesara  
Genetic Analysis: S. Hosseini-Asl  
Data Analysis / Interpretation: F. Salehzadeh  
Drafting of the Manuscript: S. Habibzadeh; S. Jahangiri  
Critical Revision of the Manuscript: S. Hosseini-Asl; F. Salehzadeh  
All authors approved final version of the Article

**Conflict of Interest:** None

**References**

1. Marshall GS, Edwards KM, Butler J, et al. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr 1987;110(1):43-6.  
2. Feder HM Jr, Bialecki CA. Periodic fever associated with aphthous stomatitis, pharyngitis and cervical adenitis. Pediatr Infect Dis J 1989;8(3):186-7.
3. Yao Q, Furst DE. Autoinflammatory diseases: an update of clinical and genetic aspects. Rheumatology (Oxford) 2008;47(7):946-51.

4. Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol 2006;18(1):108-17.

5. Thomas KT, Feder HM Jr, Lawton AR, et al. Periodic fever syndrome in children. J Pediatr 1999;135(1):15-21.

6. Scholl PR. Periodic fever syndromes. Curr Opin Pediatr 2000;12(6):563-6.

7. Long SS. Syndrome of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) what it isn’t. J Pediatr 1999;135(1):1-5.

8. Padeh S, Brezniak N, Zemer D, et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome. J Pediatr 1999;135(1):98-101.

9. Cavuoto MA, Bonagura V. A case of adult-onset PFAPA. J Allergy Clin Immunol 2006;117:S212.

10. Ridder GJ, Fradis M, Berner R, et al. PFAPA syndrome: current standard of knowledge and relevance for the ENT specialist. Laryngorhinootologie 2002;81(9):635–9.

11. Caveneuve C, Geneviève D, Amelem S, et al. MEFV gene analysis in PFAPA. J Pediatr 2003;143(1):140-1.

12. Berkun Y, Levy R, Hurwitz A, et al. The Familial Mediterranean fever gene as a modifier of periodic fever, aphthous stomatitis pharyngitis, and adenopathy syndrome. Semin Arthritis Rheum 2011;40(5):467-72.

13. Gattorno M, Sormani MP, D’Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008;58(6):1823-32.

14. Gattorno M, Caorsi R, Meini A, et al. Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics 2009;124(4):e721-8.

15. Stojanov S, Hoffmann F, Kéry A, et al. Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response. Eur Cytokine Netw 2006;17(2):90-7.

16. Dagan E, Gershoni-Baruch R, Khatib I, et al. MEFV, TNF1rA, CARD15 and NLRP3 mutation analysis in PFAPA. Rheumatol Int 2010;30(5):633-6.

17. Bonyadi M, Esmaeili M, Karimi A, et al. Common Mediterranean fever gene mutations in Azeri Turkish population of Iran. Genet Test Mol Biomarkers 2010;14(1):149-51.
کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله